Pathological adaptive responses of Schwa
β
Yoon Kyung Shin; So Young Jang; Hyun Kyoung Lee; Junyang Jung; Duk Joon Suh; Su-
π
Article
π
2010
π
John Wiley and Sons
π
English
β 1001 KB
## Abstract Bortezomib, a proteasome inhibitor, has been considered as a promising anticancer drug in the treatment of recurrent multiple myeloma and some solid tumors. The bortezomibβinduced peripheral neuropathy (BIPN) is a prominent cause of doseβlimiting toxicities after bortezomib treatment. I